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Medical Informatics, University of Wisconsin, Madison, WisconsinObjective: To determine whether antim€ullerian hormone (AMH) levels predict the availability of good-quality supernumerary
blastocysts for cryopreservation.
Design: Retrospective study.
Setting: Two fertility centers.
Patient(s): First fresh IVF cycles (n¼ 247) grouped as follows: 40 women<35 year old with AMH<1 ng/mL and 77 women with AMH
1–4 ng/mL; 62 womenR35 year old with AMH <1 ng/mL, and 68 women with AMH 1–4 ng/mL.
Intervention(s): AMH level measured before IVF with ovarian stimulation protocols based on patient age and AMH level, including
short gonadotropin-releasing hormone (GnRH) agonist, GnRH antagonist, or GnRH agonist microdose ﬂare; supernumerary good-
quality blastocysts cryopreserved on days 5 or 6 after retrieval.
Main Outcome Measures(s): Supernumerary good-quality blastocysts for cryopreservation in relation to AMH levels.
Result(s): Among women <35 years of age, there was a statistically signiﬁcant difference in the number of patients with super-
numerary good-quality blastocysts for cryopreservation between the groups with AMH <1 ng/mL and AMH 1–4 ng/mL (30.0% vs.
58.4%) when adjusted for age. Among women R35 years of age, there was a statistically signiﬁcant difference in the number of
patients with supernumerary good-quality blastocyst cryopreservation between groups with AMH <1 ng/mL and AMH 1–4 ng/mL
(16.1% vs. 42.6%), when adjusted for age.
Conclusion(s): Low AMH levels are associated with a statistically signiﬁcantly lower likelihood of blastocysts for cryopreservation as
compared with higher AMH levels. This effect was seen among women both <35 and R35 years of age. Patient counseling should
include realistic expectations for the probability of good-quality supernumerary blastocysts available for cryopreservation. (FertilUse your smartphone
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VOL. 104 NO. 3 / SEPTEMBER 2015ouples who undergo in vitroC fertilization (IVF) hope to achievea live birth with their fresh cycle
as well as to have supernumerary em-
bryos cryopreserved for future attempts
at pregnancy. Antim€ullerian hormone
(AMH) has been shown to be a strong
predictor of ovarian response to gonad-
otropins and cycle cancellation (1–10).
These ﬁndings have been the633
ORIGINAL ARTICLE: ASSISTED REPRODUCTIONcenterpiece of counseling a couple regarding IVF cycle
implications based on AMH levels. Furthermore, there have
been data to suggest that AMH levels can guide the
individualization of protocols for controlled ovarian
hyperstimulation (COH) for IVF (5, 11, 12).
Because many couples desire live birth and supernumer-
ary cryopreserved embryos, more deﬁnitive information on
whether AMH levels can predict either outcome would be of
use when counseling patients. At present, the capability of
AMH levels to predict IVF outcomes such as live-birth rate re-
mains controversial: some data suggest that AMH may do so
(13), but most of the literature to date refutes the idea of a
clear cutoff AMH level beyond which pregnancy cannot be
achieved (9, 14). In terms of embryo cryopreservation, AMH
has been shown to predict the availability of pronuclear
embryos for cryopreservation in breast cancer patients (15).
In addition, several studies have found that the AMH level
may predict the availability of good-quality supernumerary
day-3 embryos for cryopreservation (16–18). We sought
to determine whether the AMH level can predict the
availability of good-quality supernumerary blastocysts for
cryopreservation.MATERIALS AND METHODS
In this retrospective study, data were reviewed from 247
ﬁrst fresh IVF cycles at two fertility centers, Austin Fertility &
Reproductive Medicine (n ¼ 128) and the University of
Wisconsin–Madison Generations Fertility Care (n ¼ 119),
from January 2013 through December 2014. The AMH level
was measured (Beckman Coulter Gen II assay; Associated
Regional University Pathologists, Salt Lake City, UT, or Ansh
Laboratories, Webster, TX) for each patient in proximity to (at
most within 1 year) of COH (19). The exclusion criteria included
donor oocyte IVF cases, autologous oocyte IVF cases for women
with AMH >4 ng/mL, and women with no fresh transfer
whether because of a freeze-all request for preimplantation ge-
netic screening/preimplantation genetic testing or a medical
indication such as severe ovarian hyperstimulation syndrome.
An AMH level of >1 ng/mL regardless of cycle day was
considered to be normal (20, 21). The women were grouped
as follows: <35 years of age with AMH <1 ng/mL (n ¼ 40)
or AMH of 1–4 ng/mL (n ¼ 77); andR35 years of age with
AMH <1 ng/mL (n ¼ 62) or AMH of 1–4 ng/mL (n ¼ 68).
The primary outcome measure was supernumerary good-
quality blastocyst cryopreservation; the secondary outcome
measure was the clinical pregnancy rate, which was the per-
centage of patients with at least one fetal pole in the uterine
cavity with fetal cardiac motion detected by transvaginal
sonogram at 6 to 7 weeks of gestation. Institutional review
board approval was obtained from the Austin Multi-
Institutional Review Board and from the institutional review
board at the University of Wisconsin–Madison.
Individualized ovarian stimulation protocols based on
patient age and AMH level were used, including the short
gonadotropin-releasing hormone (GnRH) agonist, GnRH
antagonist, and GnRH-agonist microdose ﬂare protocols.
After ovarian stimulation and subsequent oocyte retrieval
35–36 hours after human chorionic gonadotropin (hCG)634administration, either IVF or intracytoplasmic sperm injec-
tion (ICSI) was performed; the embryo transfer was per-
formed on day 3 or day 5 based on embryo quality and in
accordance with the American Society for Reproductive
Medicine/Society for Assisted Reproductive Technology
(ASRM/SART) guidelines for the number of embryos to be
transferred (22). Supernumerary good-quality blastocysts,
deﬁned as a blastocyst score of 3BB or better in accordance
with the Gardner embryo grading system, were cryopre-
served on day 5 or day 6 (23, 24).
The effect of age and AMH on the probability of preg-
nancy and blastocyst preservation was assessed using logistic
regression. Age (AMH) was evaluated as a linear predictor, as
a 3 (4) category predictor and as a 2 category predictor with
cut-point ¼ 35 (¼1). In the case of pregnancy, AMH alone
provided a better ﬁt than age alone (evaluated using Aikake
Information Criterion). Additionally, age was not a statisti-
cally signiﬁcant predictor for models that included AMH.
For blastocyst preservation, the best model included terms
for both age and AMH. The interaction term was not statisti-
cally signiﬁcant. In all cases, the best model ﬁts were obtained
using two category versions of both age and AMH. P< .05 was
considered statistically signiﬁcant.
RESULTS
Among women <35 years of age, the mean ages for AMH
<1 ng/mL and AMH of 1–4 ng/mL were 31.3 and 30.3 years,
respectively. The 1-year difference in mean ages between
these AMH subgroups was clinically small but statistically
signiﬁcant (P¼ .048). Among women <35 years of age, there
was a statistically signiﬁcant difference in whether supernu-
merary good-quality blastocysts were available for cryopres-
ervation between women with AMH <1 ng/mL and AMH of
1–4 ng/mL (30.0% vs. 58.4%; P¼ .0002) (Table 1, Fig. 1).
AmongwomenR35 years of age, themean ages for AMH
<1 ng/mL andAMH of 1–4 ng/mLwere 38.4 and 37.2, respec-
tively; again, the 1.2-year difference in mean ages between
these subgroups was clinically small though statistically sig-
niﬁcant (P¼ .001). Among women R35 years of age, there
was a statistically signiﬁcant difference in whether supernu-
merary good-quality blastocysts were available for cryopres-
ervation between women with AMH <1 ng/mL and AMH of
1–4 ng/mL (16.1% vs. 42.6%; P¼ .0002) (see Table 1, Fig. 1).
Among women<35 years of age, there was a statistically
signiﬁcant difference (P¼ .0212) in the clinical pregnancy
rate between women with AMH <1 ng/mL and AMH of 1–
4 ng/mL (40.0% vs. 57.1%) (see Table 1). Among women
R35 years of age, there was a statistically signiﬁcant differ-
ence (P¼ .0074) in the clinical pregnancy rate between
women with AMH <1 ng/mL and AMH of 1–4 ng/mL,
providing a clinically meaningful dichotomy in outcomes
for AMH lower or greater than 1 in this age group (22.6%
vs. 51.5%) (see Table 1).
DISCUSSION
Since the establishment of the correlation between AMH
levels and ovarian response, there has been increased atten-
tion focused on AMH in the realm of assisted reproduction.VOL. 104 NO. 3 / SEPTEMBER 2015
TABLE 1








Age ‡35, AMH 1–4
(n[ 68)
Stimulation protocol (count)a
Antagonist 15 (37.5%) 10 (13.0%) 28 (45.2%) 35 (51.5%)
Agonist 10 (25.0%) 64 (83.1%) 4 (6.4%) 25 (36.7%)
Flare 15 (37.5%) 3 (3.9%) 30 (48.4%) 8 (11.8%)
ETa
Day 3 15 (37.5%) 23 (30.0%) 36 (58.0%) 29 (42.7%)
Day 5 12 (30.0%) 47 (61.0%) 13 (21.0%) 36 (52.9%)
None 13 (32.5%) 7 (9.0%) 13 (21.0%) 3 (4.4%)
Pregnancyb 40.0 (25.8, 55.5) 57.1 (46, 67.8) 22.6 (13.4, 34.0) 51.5 (39.7, 63.1)
Cryopreservationb 30.0 (17.3, 45.1) 58.4 (47.3, 69.0) 16.1 (8.4, 26.6) 42.6 (31.3, 54.5)
Age (y)c 31.3 (30.5, 32) 30.3 (29.7, 30.9) 38.4 (37.9, 39) 37.2 (36.7, 37.6)
Mean AMH (ng/mL)c 0.6 (0.5, 0.7) 2.3 (2.1, 2.5) 0.5 (0.4, 0.6) 2.1 (1.9, 2.2)
Total gonadotropin dose (IU)c 3,878 (3,491, 4,265) 2,379 (2,218, 2,541) 3,996 (3,682, 4,310) 2,718 (2,500, 2,937)
Peak E2 level (pg/mL)
c 1,587 (1,278, 1,896) 2,583 (2,328, 2,837) 1,336 (1,108, 1,565) 2,215 (1,972, 2,458)
No. of mature oocytes retrievedc 5.4 (4.7, 6.1) 10.8 (10.1, 11.6) 4.8 (4.3, 5.4) 10.4 (9.6, 11.2)
No. of 2PN zygotesc 4 (3.4, 4.7) 7.8 (7.2, 8.4) 3.7 (3.3, 4.2) 7.6 (6.9, 8.2)
No. of blasts cryopreservedc 0.8 (0.5, 1.1) 2.4 (2, 2.7) 0.5 (0.3, 0.6) 2 (1.7, 2.4)
No. of embryos transferred per ETc 1.3 (1, 1.7) 1.5 (1.2, 1.8) 2 (1.6, 2.3) 1.8 (1.5, 2.1)
Note:Outcomes of patients undergoing stimulation and type of protocol, in patients undergoing day-3 versus day-5 embryo transfer; Includes percentage of patients with supernumerary blastocyst
cryopreservation and clinical pregnancy; study variables including age, AMH level (ng/mL), total gonadotropin dose (IU), peak estradiol level (pg/mL), number of mature oocytes retrieved, number of
2PN zygotes, number of blastocysts (blasts) cryopreserved, and number of embryos transferred per ET. AMH¼ antim€ullerian hormone; E2¼ estradiol; ET ¼ embryo transfer; 2PN¼ two pronuclei.
a Number and percentage of patients.
b Percentage of patients and 95% conﬁdence interval.
c Mean and 95% conﬁdence interval.
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FIGURE 1
Among women <35 years of age, availability of supernumerary
good-quality blastocysts for cryopreservation between groups of
AMH <1 ng/mL and AMH of 1–4 ng/mL (30.0% vs 58.4%;
*P¼.0002). Data are expressed as mean values  conﬁdence
interval. Among women R35 years of age, availability of
supernumerary good-quality blastocysts for cryopreservation
between groups of AMH <1 ng/mL and AMH of 1–4 ng/mL
(16.1% vs 42.6%; **P¼.0002). Data are expressed as mean values
 conﬁdence interval.
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Fertility and Sterility®Lee et al. (15) demonstrated that an AMH level <1.2 ng/mL is
a determinant of successful embryo/oocyte cryopreservation
in breast cancer patients who were stimulated with letrozole
and follicle-stimulating hormone. Due to the speciﬁc po-
pulation of breast cancer patients and their goal of fertility
preservation in that study, embryo cryopreservation was a
freeze-all condition performed at the pronuclear stage.
Several studies have examined whether AMH levels are asso-
ciated with successful supernumerary embryo cryopreservation,
with some data showing a statistically signiﬁcant correla-
tion (16–18) and other data showing no difference (25).
The cryopreservation of supernumerary embryos in the
aforementioned studies was performed on day 3. A recent
study showed a positive relationship between AMH levels
and blastocyst availability for fresh transfer as well as for
blastocyst cryopreservation among good-prognosis patients
only with high AMH levels; the threshold for the 25th quartile
in that study was an AMH of 13 pmol/L or 5.79 ng/mL, and
the threshold for the 75th quartile was 37 pmol/L or
16.47 ng/mL (26).
Several limitations of our study included the use of
various COH protocols and the transfer of more than one em-
bryo in certain fresh embryo transfer cases. The different COH
protocols used were based on the patient's age, AMH level,
and, when applicable, prior response to ovulation induction.
Although elective single-embryo transfer was offered and
performed for patients who were appropriate candidates, in
some cases more than one fresh embryo were transferred in
accordance with ASRM/SART guidelines. If elective single-
embryo transfer were applied for every patient, particularly635
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the IVF outcomes for couples would potentially be compro-
mised; therefore, the transfer of more than one embryo in
certain cases does reﬂect current practice and may make the
results of our study more applicable to clinical practice.
Only one case was excluded (with seven frozen embryos),
involving a freeze-all in order to prevent severe ovarian hy-
perstimulation syndrome, which had no effect on the statisti-
cal analyses. A strength of our study was the exclusion of
patients with AMH >4 ng/mL, thus providing a conservative
statistical estimation of supernumerary blastocyst cryopres-
ervation in the AMH of 1–4 ng/mL group.
Based on our results, it appears that patients with an AMH
<1 ng/mL had a statistically signiﬁcantly lower probability of
successful supernumerary blastocyst cryopreservation as
compared with those with AMH of 1–4 ng/mL. This effect
was seen among women <35 years of age as well as among
those R35 years of age. Our study suggests that low AMH
levels are associated with a signiﬁcantly lower likelihood of
blastocyst cryopreservation as compared with higher AMH
levels. Patient counseling should include realistic expecta-
tions not only for ovarian stimulation and live-birth rates
but also for the probability of good-quality supernumerary
blastocyst cryopreservation.
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